• Markets
    • icon
  • Companies
CYC · ASX

Cyclopharm Limited (ASX:CYC)

AU$1.99

 -0.01 (-0.5%)
ASX:Live
08/12/2023 03:46:19 PM
Recent Earnings downgrade HALO Ords GROWTH AUS EMA 125 Breakdown All-Consensus +1
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

CYC Overview

CYC Health Scores

Short Term

Mean Revision

Trend

Event

Halo Model

MQV

GARP

MQV Small

Valuation

Value

Consensus

Momentum

Price

Earnings

Growth

Earnings

Dividends

Quality

Capital Efficiency

Balance Sheet

About CYC

Website

Cyclopharm Limited

Telephone

61.2.9541.0411

Address

Unit 4 1 The Crescent Kingsgrove, New South Wales (NSW) 2208

Description

Cyclopharm Ltd. is a radiopharmaceutical company, which engages in the diagnostic imaging in lung health. It manufactures and sells medical devices and pharmaceutical products. The firm operates through Technegas and Molecular Imaging segments. The Technegas segment supplies diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism. The Molecular Imaging segment produces radiopharmaceuticals to be used by physicians in the detection of cancer, neurological disorders and cardiac disease. The company was founded in 1984 and is headquartered in Kingsgrove, Australia.

CYC Price Chart

Key Stats

Market Cap

AU$188.19M

PE

0.00

EV/EBITDA

0.0

Dividends Overview

DIV Yield

.8%

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 1.15 - 3.15

Trade Value (12mth)

AU$12,064.00

1 week

-1%

1 month

-0.5%

YTD

67.93%

1 year

50.76%

All time high

3.45

Key Fundamentals

EPS 3 yr Growth

67.500%

EBITDA Margin

-27.30%

Operating Cashflow

-$7m

Free Cash Flow Return

-15.10%

ROIC

-15.00%

Interest Coverage

-23.90

Quick Ratio

3.60

Other Data

Shares on Issue (Fully Dilluted)

92m

HALO Sector

Healthcare

Next Company Report Date

21-Feb-24

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

CYC Announcements

Latest Announcements

Date Announcements

31 March 23

Annual Report to shareholders

×

Annual Report to shareholders

31 March 23

Appendix 4G

×

Appendix 4G

31 March 22

Annual Report to shareholders

×

Annual Report to shareholders

31 March 22

Appendix 4G

×

Appendix 4G

31 March 20

Annual Report to shareholders

×

Annual Report to shareholders

31 March 15

Annual Report to shareholders

×

Annual Report to shareholders

31 March 14

Annual Report to shareholders

×

Annual Report to shareholders

30 November 22

Change of Director's Interest Notice - DAngus

×

Change of Director's Interest Notice - DAngus

30 March 23

Technegas Enters Final Six Month USFDA Review Cycle

×

Technegas Enters Final Six Month USFDA Review Cycle

30 March 21

Notice of Annual General Meeting/Proxy Form

×

Notice of Annual General Meeting/Proxy Form

29 November 22

Cyclopharm Receives $1.64m R&D Refund

×

Cyclopharm Receives $1.64m R&D Refund

29 May 18

CYC 2018 AGM Presentation

×

CYC 2018 AGM Presentation

29 March 21

Annual Report to shareholders

×

Annual Report to shareholders

29 March 19

Annual Report to shareholders

×

Annual Report to shareholders

28 May 12

AGM Presentation Audio Broadcast

×

AGM Presentation Audio Broadcast

28 March 17

CYC Annual Report to Shareholders

×

CYC Annual Report to Shareholders

28 March 13

Annual Report to shareholders

×

Annual Report to shareholders

28 August 17

Cyclopharm Limited 1H2017 Results Investor Presentation

×

Cyclopharm Limited 1H2017 Results Investor Presentation

28 August 07

Half Year Presentation

×

Half Year Presentation

27 September 22

Initial Director's Interest Notice

×

Initial Director's Interest Notice

27 September 22

CYC Board Changes

×

CYC Board Changes

27 May 08

2008 AGM Presentation - Audio Broadcast

×

2008 AGM Presentation - Audio Broadcast

27 March 12

Annual Report to shareholders

×

Annual Report to shareholders

27 July 15

CYC Investor Presentation July 2015

×

CYC Investor Presentation July 2015

27 April 18

Notice of Annual General Meeting/Proxy Form

×

Notice of Annual General Meeting/Proxy Form

26 September 23

Cyclopharm Investor Update

×

Cyclopharm Investor Update

26 September 23

Investor Presentation Correction

×

Investor Presentation Correction

26 September 23

Investor Presentation Correction

×

Investor Presentation Correction

CYC Fundamentals

Per Share Records

Historical data

Forecasted data

AUD 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.08 -0.06 -0.07 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.08 -0.06 -0.07 Lock Lock Lock
     Growth % Lock Lock Lock Lock -84.3 28.6 -27.4 Lock Lock Lock
     PE X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.05 -0.03 -0.06 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.13 -0.04 -0.10 Lock Lock Lock
     Growth % Lock Lock Lock Lock -137.4 33.6 -63.7 Lock Lock Lock
     Yield % Lock Lock Lock Lock -5.2 -2.3 -8.2 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.01 0.01 0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
     Yield % Lock Lock Lock Lock 0.4 0.6 0.8 Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.21 0.46 0.39 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.15 0.40 0.33 Lock Lock Lock
     Growth % Lock Lock Lock Lock -36.2 173.7 -17.1 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 77 90 92 Lock Lock Lock
Basic m Lock Lock Lock Lock 77 90 92 Lock Lock Lock

Financial Records

Historical data

Forecasted data

AUD 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Income Statement
Sales $m Lock Lock Lock Lock 15 18 23 Lock Lock Lock
     Growth % Lock Lock Lock Lock 4.2 20.6 31.1 Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 10 10 13 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 2 3 6 Lock Lock Lock
     Growth % Lock Lock Lock Lock -57.3 54.0 85.5 Lock Lock Lock
     Margin % Lock Lock Lock Lock 14.2 18.1 25.6 Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 86 82 74 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -7 -6 -6 Lock Lock Lock
     Growth % Lock Lock Lock Lock -46.6 20.9 -11.9 Lock Lock Lock
     Margin % Lock Lock Lock Lock -48.9 -32.1 -27.3 Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 1 1 1 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -8 -6 -7 Lock Lock Lock
     Growth % Lock Lock Lock Lock -37.2 20.4 -13.1 Lock Lock Lock
     Margin % Lock Lock Lock Lock -55.1 -36.3 -31.4 Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -9 -7 -8 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -3 -2 -1 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -6 -5 -7 Lock Lock Lock
     Growth % Lock Lock Lock Lock -107.5 16.6 -31.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock -41.2 -28.5 -28.5 Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -9 -2 -7 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 1 1 2 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock -1 -1 -2 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock -1 30 -1 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -9 -2 -8 Lock Lock Lock
     Growth % Lock Lock Lock Lock -1,630.4 72.9 -221.1 Lock Lock Lock
     Margin % Lock Lock Lock Lock -0.6 -0.1 -0.3 Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 2 29 20 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 28 56 50 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 5 4 4 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock 3 -25 -16 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 11 13 13 Lock Lock Lock
Equity $m Lock Lock Lock Lock 17 43 37 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 22 47 41 Lock Lock Lock
     Growth % Lock Lock Lock Lock -22.5 118.7 -14.2 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -21.4 -9.0 -13.3 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -35.3 -11.7 -18.1 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -32.4 -18.5 -16.5 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -24.4 -14.6 -15.0 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -36.0 -4.7 -15.1 Lock Lock Lock

Ratios Records

Historical data

Forecasted data

AUD 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Leverage
Interest Cover X Lock Lock Lock Lock -34.5 -63.5 -23.9 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock -0.4 4.4 2.5 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock 16.5 -57.4 -43.7 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 2.8 5.8 4.6 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 2.0 5.1 3.6 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 11.7 67.6 55.0 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -157.2 -22.0 -84.0 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 2.2 2.1 2.9 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 3.5 2.8 2.5 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 1.4 0.5 0.8 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 22.5 12.3 18.9 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.5 0.3 0.5 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.5 0.3 0.5 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock -60.3 -37.5 -33.0 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock -31.3 -11.9 -15.5 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -21.4 -9.0 -13.3 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.7 1.3 1.4 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -35.3 -11.7 -18.1 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 112.7 117.8 113.9 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -39.8 -13.8 -20.6 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 104.8 129.0 145.8 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 165.1 177.0 124.3 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 269.9 306.0 270.1 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 57.9 65.4 59.8 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock 212.0 240.6 210.3 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

.8%

Franking Level

N/A

DPSg

0.00%

Quality Yield

Lock

Falling Divs over next 2

Lock

Expected Dividend Cashflow

Dividend Clarity,
Enhanced
Strategy

Upload your portfolio and gain access to 3-year dividend forecasts for each holding with HALO Global. Empower your decision-making and maximize returns with our advanced analytical tool. Try it today.

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

CYC Shortsell

Frequently Asked Questions

The current share price of Cyclopharm Limited (CYC:ASX) is AU$1.99.
The 52-week high share price for Cyclopharm Limited (CYC:ASX) is AU$3.15.
The 52-week low share price for Cyclopharm Limited (CYC:ASX)? is AU$1.15.
The current TTM dividend payout for Cyclopharm Limited (CYC:ASX) is 0.80.
The last dividend payment of Cyclopharm Limited (CYC:ASX) is AU$0.01.
Cyclopharm Limited (CYC:ASX) has a franking level of 0%.
Cyclopharm Limited (CYC:ASX) is classified in the Healthcare.
The current P/E ratio for Cyclopharm Limited (CYC:ASX) is 0.00.
halo-logo-inverted-rgb@72ppi-1
Login
Products
Company
Important

Get the latest insights and hot tips delivered right to your inbox

Apple Store
Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.